CLINICAL_TRIALS
other
· 2026-02-05
Clinical Trial Update: Treating Patients With Melanoma and ALK Alterations With Ensartinib [Phase 2]
Summary
Phase 2 study evaluating ensartinib in melanoma patients with ALK alterations; the trial is currently active but not recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING